Key result
Elevated baseline NT-proBNP linked to ~2.9-fold higher cardiovascular event risk in SLE.
Why the study?
Strategies for identifying individuals at high risk of cardiovascular events in systemic lupus erythematosus are lacking. Although a previous cross-sectional study linked NT-proBNP > 133 pg/mL to cardiovascular damage, its association with incident cardiovascular events needed assessment.
Does a baseline NT-proBNP level > 133 pg/mL predict future cardiovascular events in patients with systemic lupus erythematosus without prior cardiovascular disease?
Cohort (n=351)
Yes
Does a baseline NT-proBNP level > 133 pg/mL predict future cardiovascular events in patients with systemic lupus erythematosus without prior cardiovascular disease?
An NT-proBNP threshold of 133 pg/mL independently predicts incident cardiovascular events in patients with systemic lupus erythematosus and may help guide cardiovascular risk stratification.
Answers are grounded in this paper and cite their sources.
May support NT-proBNP for CVE risk stratification in SLE; hypothesis-generating and requires validation before clinical adoption.
Objective Current strategies for identifying individuals at high risk of cardiovascular events (CVE) in systemic lupus erythematosus (SLE) are lacking. A previous cross-sectional study in SLE showed that NT-proBNP > 133 pg/mL was associated with cardiovascular damage. Our objective was to assess the association between NT-proBNP at a threshold of 133 and incident CVE in SLE. Methods All SLE patients who were included in the randomised controlled trial PLUS between 2007 and 2010 in France were screened. Patients with a history of CVE, an unavailable serum sample at PLUS inclusion, or incomplete follow-up were excluded from the primary analysis. The primary endpoint was the occurrence of CVE during follow-up. Results A total of 351 patients (out of 573 included in PLUS) were analyzed. Of these patients, 316 (90.0%) were women with a median age of 38 [30-48] years. Among them, 24 (6.8%) patients experienced at least one CVE that occurred a median of 5 [3-7] years after baseline. Five patients had more than one CVE. In the multivariable analysis, age, dyslipidemia and NT-proBNP were significantly associated with the occurrence of CVE. NT-proBNP was >133pg/mL in 22 (6.3%) patients at baseline. The 133 pg/ml threshold was significantly associated with the occurrence of CVE during follow-up (adjusted hazard ratio [CI 95]: 2.94; 95% CI: 1.12–7.71). Conclusion A NT-proBNP threshold of 133 pg/ml is associated with future CVE in SLE. SLE care guidelines could consider including NT-proBNP measurement in order to better stratify the cardiovascular prevention strategies in this high-risk population.
No takes yet. Share an insight, caveat, or question.
Mageau et al. (2026) conducted a cohort in Systemic lupus erythematosus (SLE) (n=351). Baseline NT-proBNP > 133 pg/mL vs. Baseline NT-proBNP <= 133 pg/mL was evaluated on Occurrence of cardiovascular events (CVE) during follow-up (HR 2.94, 95% CI 1.12-7.71). Baseline NT-proBNP > 133 pg/mL was associated with incident cardiovascular events in patients with SLE.
Synapse has enriched 10 related papers. Consider them for comparative context: